Ceribell Q2 FY26 net loss widens 41% to $19.27 million; revenue rises 33% to $28.1 million
CBLL•Adoption and FDA clearances
The Ceribell System surpassed 700 hospital adoptions; it also received FDA 510(k) clearances in June 2026 for two algorithms and next-generation hardware.
Losses widen, gross margin improves
Net loss widened to $19.3 million from $13.6 million a year earlier; operating loss widened to $20 million from $15 million.
Gross margin rose 4 percentage points to 92%, helped by lower product cost of goods sold that included a $1 million tariff refund.
Adjusted EBITDA (non-GAAP) improved to a loss of $9.8 million from a loss of $10 million, excluding stock-based compensation and IP litigation costs.
Q2 revenue rises 33% to $28.1 million
Ceribell reported Q2 revenue of $28.1 million, up 33% year over year, driven by product revenue of $21.2 million and subscription revenue of .
